Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
<!-- Name:DistributionId Value:8805131 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Medexus Pharmaceuticals Inc
Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7…
<!-- Name:DistributionId Value:8745700 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Medexus Welcomes Two New Board Members
<!-- Name:DistributionId Value:8743555 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA
Additional data collection and analysis reconfirms confidence in New Drug Application for TreosulfanNDA resubmission date consistent with previously announced timelineFDA decision still…
Medexus Pharmaceuticals Announces Type A Meeting with FDA Granted for Treosulfan
TORONTO and CHICAGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) today announced that…
Medexus to Present at Canaccord Genuity’s 41st Annual Growth Conference
TORONTO and CHICAGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it will be presenting at…
Medexus Announces Availability of Triamcinolone Hexacetonide in the United States
TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today…